Preclinical News and Research

RSS
TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

Amorfix second quarter net loss decreases to $25,728

Amorfix second quarter net loss decreases to $25,728

CytomX awarded $488,000 as grant under QTDP Program

CytomX awarded $488,000 as grant under QTDP Program

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

NovaBay third quarter net loss increases to $1.6 million

NovaBay third quarter net loss increases to $1.6 million

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Exhausted neurons die prematurely and trigger disease symptoms

Exhausted neurons die prematurely and trigger disease symptoms

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Zalicus third quarter total revenue decreases to $1.2 million

Zalicus third quarter total revenue decreases to $1.2 million

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.